Efficacy of anlotinib plus immune checkpoint inhibitors in soft-tissue sarcoma: systematic review and meta-analysis
- 14 September 2026
- journal article
- review article
- Published by Taylor & Francis in Future Oncology
- Vol. 22 (22) , 2717-2731
Abstract
1. Sarcomas are rare and heterogeneous mesenchymal malignancies, constituting approximately 1% of adult cancers [1] and an even larger proportion of pediatric cancers [2], with a vast array of hist...Keywords
This publication has 65 references indexed in Scilit:
- Twenty‐five years without progress: The enduring challenge of soft tissue sarcomasCancer, 2025
- Pazopanib in the real-world setting in soft tissue sarcomas: data from the Italian national registryESMO Open, 2024
- The efficacy and safety of anlotinib combined with chemotherapy in treatment of advanced soft tissue sarcomaDiscover Oncology, 2024
- Efficacy and safety of anlotinib plus penpulimab as second-line treatment for small cell lung cancer: A multicenter, open-label, single-arm phase II trialCancer Pathogenesis and Therapy, 2024
- The Perils of Misinterpreting and Misusing “Publication Bias” in Meta-analyses: An Education Review on Funnel Plot-Based MethodsSports Medicine, 2023
- Soft tissue and visceral sarcomas: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up☆Annals of Oncology, 2021
- Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of InterventionsCochrane Database of Systematic Reviews, 2019
- Contemporary management of metastatic soft tissue sarcomaCurrent Problems in Cancer, 2019
- Tumor response assessment by modified Choi criteria in localized high‐risk soft tissue sarcoma treated with chemotherapyCancer, 2012
- Trends in the incidence of soft tissue sarcomas in the United States from 1973 through 1987Cancer, 1993